368 related articles for article (PubMed ID: 30941139)
1. Ectonucleotidases in Intestinal and Hepatic Inflammation.
Vuerich M; Robson SC; Longhi MS
Front Immunol; 2019; 10():507. PubMed ID: 30941139
[TBL] [Abstract][Full Text] [Related]
2. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the T Cell Response by CD39.
Takenaka MC; Robson S; Quintana FJ
Trends Immunol; 2016 Jul; 37(7):427-439. PubMed ID: 27236363
[TBL] [Abstract][Full Text] [Related]
4. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
5. Targeting ectonucleotidases to treat inflammation and halt cancer development in the gut.
Longhi MS; Feng L; Robson SC
Biochem Pharmacol; 2021 May; 187():114417. PubMed ID: 33460629
[TBL] [Abstract][Full Text] [Related]
6. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of engineered bifunctional fusion proteins of CD39 and CD73 ectonucleotidases.
Zhong EH; Ledderose C; De Andrade Mello P; Enjyoji K; Lunderberg JM; Junger W; Robson SC
Am J Physiol Cell Physiol; 2021 Jan; 320(1):C15-C29. PubMed ID: 33052071
[TBL] [Abstract][Full Text] [Related]
8. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
9. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
10. Biochemical analysis of ectonucleotidases on primary rat vascular smooth muscle cells and in silico investigation of their role in vascular diseases.
Bertoni APS; de Campos RP; Tamajusuku ASK; Stefani GP; Braganhol E; Battastini AMO; Wink MR
Life Sci; 2020 Sep; 256():117862. PubMed ID: 32473244
[TBL] [Abstract][Full Text] [Related]
11. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
12. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
13. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
14. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
15. Human platelets express functional ectonucleotidases that restrict platelet activation signaling.
Chaurasia SN; Kushwaha G; Pandey A; Dash D
Biochem Biophys Res Commun; 2020 Jun; 527(1):104-109. PubMed ID: 32446352
[TBL] [Abstract][Full Text] [Related]
16. Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways.
Morianos I; Trochoutsou AI; Papadopoulou G; Semitekolou M; Banos A; Konstantopoulos D; Manousopoulou A; Kapasa M; Wei P; Lomenick B; Belaidi E; Kalamatas T; Karageorgiou K; Doskas T; Sallusto F; Pan F; Garbis SD; Quintana FJ; Xanthou G
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12269-12280. PubMed ID: 32409602
[TBL] [Abstract][Full Text] [Related]
17. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
18. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and hypertension: Pivotal involvement of purinergic signaling.
Reichert KP; Castro MFV; Assmann CE; Bottari NB; Miron VV; Cardoso A; Stefanello N; Morsch VMM; Schetinger MRC
Biomed Pharmacother; 2021 May; 137():111273. PubMed ID: 33524787
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves.
Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
